Background
Methods
Patients
Study design
Medication
Biomarker analysis
Liver histopathology
RT-PCR analysis
Statistical analysis
Results
Study group characteristics
Number of patients | ||
---|---|---|
Duration of treatment | < 1 year | >1 year |
Treatment-related mortality | - | - |
Hepatocarcinoma | - | 1 |
Hepato-renal syndrome | - | 1 |
Esophagic varices bleeding | - | 1 |
Heart attack | - | 1 |
Percent of enrolled patients death | 0% | 9% |
Symptoms |
*n = 28 | % |
**n = 34 | % |
---|---|---|---|---|
Gastritis | 17 | 81% | 23 | 67% |
Nausea | 10 | 48% | 12 | 35% |
Rash | 10 | 48% | 10 | 29% |
Photosensitivity | 3 | 14% | 3 | 9% |
Headache | 3 | 14% | 4 | 12% |
Vomiting | 1 | 5% | 1 | 3% |
Dizziness | 2 | 10% | 2 | 6% |
Weakness | 2 | 10% | 2 | 6% |
Insomnia | 1 | 5% | 1 | 3% |
Somnolence | 1 | 5% | 1 | 3% |
Characteristics |
n= 34 | |
---|---|---|
Sex | Male, n (%) | 13 (38%) |
Female, n (%) | 21 (62%) | |
Age at exposure (yr) | Mean ± SD | 27 ± 9 |
Age at liver biopsy before treatment (yr) | Mean ± SD | 56 ± 10 |
Age at liver biopsy after treatment (yr) | Mean ± SD | 58 ± 10 |
Route of transmission | Blood transfusion, n (%) | 29 (85%) |
Nosocomial, n (%) | 5 (15%) | |
Duration of HCV exposure (yr) | Mean ± SD | 32 ± 10 |
HCV genotype | Genotype 1, n (%) | 24 (70%)& |
Genotype 2, n (%) | 4 (12%)& | |
Genotype 3, n (%) | 2 (6%) | |
ND, n (%) | 5 (15%) | |
Change in HCV viral load after treatment | Increase 1 log, n (%) | 1 (4%) |
Unchanged*, n (%) | 27 (96%) | |
Body mass index (Kg/m2) | Mean (±SD) | 28 ± 7**
|
Characteristics of dropping-out patients
Child-pugh score | |||||
---|---|---|---|---|---|
Treatment | No. patients | Statistics | Before | After |
P value
|
< 2 years | 6 | Minimum | 5 (A) | 6 (A) |
0.2
|
Median | 6.5 (A) | 9 (B) | |||
Maximum | 10 (C) | 9 (B) | |||
2 years | 28 | Minimum | 5 (A) | 5 (A) |
0.8
|
Median | 5.5 (A) | 6 (A) | |||
Maximum | 10 (C) | 12 (C) | |||
Intention to treat | 34 | Minimum | 5 (A) | 5 (A) |
0.6
|
Median | 6 (A) | 6 (A) | |||
Maximum | 10 (C) | 9 (B) |
Effect of PFD on liver biochemistry and clinical data
Treat | < 2 years | 2 years | Intention to treat | ||||||
---|---|---|---|---|---|---|---|---|---|
No. patients | 6 | 28 | 34 | ||||||
Biochemical data | Before | After |
P value
| Before | After |
P value
| Before | After |
P value
|
ALT (mean ± SD) | 67 ± 25 | 59 ± 20 |
0.63
| 85 ± 71 | 65 ± 34 |
0.13
| 82 ± 68 | 64 ± 32 |
0.23
|
AST (mean ± SD) | 95 ± 38 | 87 ± 38 |
1.0
| 94 ± 55 | 75 ± 38 |
0.02*
| 94 ± 54 | 78 ± 38 |
0.02*
|
Total Bilirubin (mean ± SD) | 2 ± 1.7 | 3.1 ± 1.5 |
0.16
| 1 ± 0.8 | 1 ± 0.5 |
0.04*
| 1.4 ± 0.9 | 1.4 ± 1.1 |
0.46
|
Direct Bilirubin (mean ± SD) | 0.8 ± 0.5 | 1.5 ± 0.9 |
0.03*
| 0.4 ± 0.3 | 0.4 ± 0.2 |
0.63
| 0.5 ± 0.3 | 0.6 ± 0.6 |
0.46
|
Indirect Bilirubin (mean ± SD) | 1.3 ± 0.9 | 1.6 ± 0.9 |
0.56
| 0.8 ± 0.7 | 0.6 ± 0.4 |
0.05*
| 0.9 ± 0.7 | 0.8 ± 0.6 |
0.31
|
Child-Pugh score in enrolled patients
Intention to treat analysis for quality of life
Domains (mean ± SD) | SF-36* before | SF-36* after |
P value
|
---|---|---|---|
Physical function | 69 ± 30 | 82 ± 23 |
0.00**
|
Role physical | 61 ± 47 | 86 ± 32 |
0.02**
|
Body pain | 70 ± 26 | 81 ± 19 |
0.00**
|
General health | 55 ± 21 | 73 ± 18 |
0.00**
|
Vitality | 62 ± 24 | 73 ± 22 |
0.02**
|
Social functioning | 73 ± 29 | 81 ± 23 |
0.03**
|
Role emotional | 68 ± 45 | 83 ± 38 |
0.17
|
Mental health | 75 ± 20 | 83 ± 17 |
0.00**
|